免疫检查点抑制剂（ICIs）展示了无与伦比的临床反应，并彻底改变了肿瘤治疗的范式，然而相当多的患者对于ICIs单药治疗仍然无反应或者产生抵抗，这可以追溯到细胞代谢功能的失调。虽然代谢紊乱长久以来一直被认定为肿瘤的标志，但如今越来越多的人接受了这种观点：代谢重编程并不仅仅是肿瘤细胞的专属特征，同样也是免疫细胞的特征。因此，在实质上，人们更多地关注的是肿瘤细胞代谢对免疫细胞的影响。然而，在实践中，免疫细胞在其激活和分化过程中与其自身的代谢功能密切互动，这是一个前所未有的新领域，被称为免疫代谢。对于肿瘤浸润的免疫细胞进行代谢干预可能会提供新的机会，打破抵抗性并改善已有的ICIs免疫治疗，其关键可能在于确定代谢干预与ICIs的协同组合，以获取协同效应并促进调整的抗肿瘤免疫反应。在此，我们从代谢重编程的新维度，详细阐述了多种肿瘤浸润的免疫细胞的免疫治疗抵抗的潜在机制，以及相关的代谢干预，希望为针对代谢易感性以绕过免疫治疗抵抗提供参考。© 2023. 高等教育出版社 (Higher Education Press)。

Immune checkpoint inhibitors (ICIs) have demonstrated unparalleled clinical responses and revolutionized the paradigm of tumor treatment, while substantial patients remain unresponsive or develop resistance to ICIs as a single agent, which is traceable to cellular metabolic dysfunction. Although dysregulated metabolism has long been adjudged as a hallmark of tumor, it is now increasingly accepted that metabolic reprogramming is not exclusive to tumor cells but is also characteristic of immunocytes. Correspondingly, people used to pay more attention to the effect of tumor cell metabolism on immunocytes, but in practice immunocytes interact intimately with their own metabolic function in a way that has never been realized before during their activation and differentiation, which opens up a whole new frontier called immunometabolism. The metabolic intervention for tumor-infiltrating immunocytes could offer fresh opportunities to break the resistance and ameliorate existing ICI immunotherapy, whose crux might be to ascertain synergistic combinations of metabolic intervention with ICIs to reap synergic benefits and facilitate an adjusted anti-tumor immune response. Herein, we elaborate potential mechanisms underlying immunotherapy resistance from a novel dimension of metabolic reprogramming in diverse tumor-infiltrating immunocytes, and related metabolic intervention in the hope of offering a reference for targeting metabolic vulnerabilities to circumvent immunotherapeutic resistance.© 2023. Higher Education Press.